导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.44% | 1639/4773 |
| 近一周 | -3.13% | 3728/5462 |
| 近一月 | -9.84% | 4882/5421 |
| 近一季 | -18.32% | 4683/5209 |
| 近半年 | -0.84% | 1392/4920 |
| 近一年 | 7.26% | 1334/4366 |
| 近两年 | 109.12% | 489/2954 |
| 近三年 | 62.67% | 406/2253 |
| 成立以来 | 237.47% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.43% 1799/4961 |
35.06% 927/5312 |
- - |
- - |
| 2025 | 48.73% 516/4813 |
-1.64% 2722/3635 |
3.19% 1118/4076 |
47.49% 457/4524 |
-0.66% 2581/4813 |
| 2024 | 12.77% 1213/3463 |
-4.42% 1663/2808 |
-6.29% 1906/3014 |
27.53% 218/3129 |
-1.28% 1643/3463 |
| 2023 | -18.30% 1799/2656 |
1.93% 1481/2280 |
-6.86% 1727/2385 |
-9.07% 1773/2515 |
-5.36% 1332/2655 |
| 2022 | -27.98% 1519/2207 |
-19.09% 1430/1919 |
5.65% 850/2016 |
-17.65% 1627/2113 |
2.30% 986/2208 |
| 2021 | 11.50% 401/1822 |
-6.58% 1022/1255 |
24.88% 103/1330 |
-6.35% 918/1466 |
2.05% 711/1822 |
| 2020 | 60.09% 124/1250 |
3.01% 127/1028 |
28.82% 91/1067 |
5.48% 916/1164 |
14.37% 281/1184 |
| 2019 | 40.36% 254/1092 |
32.06% 183/754 |
-9.76% 686/804 |
7.29% 95/850 |
9.79% 193/918 |
| 2018 | -26.10% 370/834 |
- - |
- - |
- - |
-10.67% 214/691 |
| 2017 | -10.82% 537/714 |
- - |
- - |
- - |
- - |
| 2016 | -24.29% 470/605 |
- - |
- - |
- - |
- - |
| 2015 | 51.62% 17/575 |
- - |
- - |
- - |
- - |
| 2014 | 10.98% 206/237 |
- - |
- - |
- - |
- - |
| 2013 | 71.42% 3/186 |
- - |
- - |
- - |
- - |
| 2012 | -1.21% 127/140 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 易方达创业板ETF联接A VS. 长安沪深300非周期A(740101) |